Publications by authors named "Bertha-Maria Nassani"
Article Synopsis
- Immune checkpoint inhibitors (ICIs) like pembrolizumab have notable clinical advantages but can cause serious side effects known as immune-related adverse events (irAEs), affecting various organ systems.
- A case study of a female patient revealed that she experienced myxedema coma (MC) and adrenal insufficiency (AI) four months after stopping treatment with pembrolizumab, necessitating treatment with levothyroxine and hydrocortisone.
- This highlights the need for careful monitoring of patients on ICIs for potential endocrine disorders, as they can lead to severe health complications if not detected early.
'Post-acute coronavirus disease 2019 (COVID-19) syndrome' is a new term that was coined to describe a constellation of persistent symptoms and new complications following recovery from COVID-19 initial illness. Identifying post-COVID-19 complications is crucial for early diagnosis and subsequent initiation of therapies to ensure more favorable outcomes. Severe COVID-19-related hemophagocytic lymphohistiocytosis (HLH) has been previously described during the acute phase of the infection.
View Article and Find Full Text PDF